Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.44 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177484 | 0.81 | EGFR (0.57) | MEN1KMT2ANPC1RAB9ASCN9A | |
| SCHEMBL30046349 | 0.80 | SCN9A (0.76) | MEN1KMT2ANPC1RAB9ASCN9A | |
| SCHEMBL3487003 | 0.78 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9ASCN9A | |
| SCHEMBL2174012 | 0.78 | SCN9A (0.61) | MEN1KMT2ANPC1RAB9ASCN9A | |
| SCHEMBL2179743 | 0.78 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9ASCN9A | |
| SCHEMBL3487000 | 0.77 | MEN1 (0.64) | MEN1KMT2ANPC1RAB9ASCN9A | |
| SCHEMBL14773108 | 0.76 | MEN1 (0.48) | MEN1KMT2ANPC1RAB9ASCN9A | |
| SCHEMBL31691382 | 0.75 | MEN1 (0.57) | MEN1KMT2ANPC1RAB9ASCN9A | |
| SCHEMBL14769593 | 0.74 | SCN9A (0.56) | MEN1KMT2ANPC1RAB9ASCN9A | |
| SCHEMBL691344 | 0.74 | MEN1 (0.59) | MEN1KMT2ANPC1RAB9ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | MEN1 301/4885KMT2A 1604/4885NPC1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.